Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal Antibody-Reference-Cited by-同舟云学术

Identification and Characterization of MEDI4736, an Antagonistic Anti–PD-L1 Monoclonal Antibody

Published:2015-05-05 Issue:9 Volume:3 Page:1052-1062
ISSN:2326-6066
Container-title:Cancer Immunology Research
language:en
Short-container-title:Cancer Immunol Res

Author:

Stewart Ross,Morrow Michelle,Hammond Scott A.,Mulgrew Kathy,Marcus Danielle,Poon Edmund,Watkins Amanda,Mullins Stefanie,Chodorge Matthieu,Andrews John,Bannister David,Dick Emily,Crawford Nicola,Parmentier Julie,Alimzhanov Marat,Babcook John S.,Foltz Ian N.,Buchanan Andrew,Bedian Vahe,Wilkinson Robert W.,McCourt Matthew

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Immunology

Cited by 335 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer;New England Journal of Medicine;2024-09-13

2. A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors;Immunotherapy;2024-09-12

3. NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer;Gynecologic Oncology;2024-09

4. PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer;Future Oncology;2024-07-18

5. Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small Cell Lung Cancer: The Phase II BALTIC Study;Clinical Cancer Research;2024-07-17